Scientists test new Two-Pronged attack on tough cancers
NCT ID NCT00740805
Summary
This early-stage study is testing a new combination of drugs for people with advanced solid tumors or non-Hodgkin lymphoma that has spread. The main goal is to find the safest and most effective dose by combining an experimental drug called veliparib with standard chemotherapy drugs. Researchers want to see if this combination can kill cancer cells more effectively than chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.